Latest News From Lumira Ventures

Forbius’ AVID200, a Novel TGF-beta 1 & 3 Inhibitor, Cleared by Health Canada to Commence Phase 1 Clinical Trial in Solid Tumors

Jennifer Schram Forbius (Formation Biologics), Portfolio News, Press Release

Expansion of ongoing AVID200 Phase 1 solid tumor trial to include patients at clinical sites in Canada AVID200 is a rationally designed, highly potent inhibitor of TGF-beta 1 & 3, the principal oncogenic TGF-beta isoforms Best-in-class efficacy and safety potential …

Forbius: First Patient Dosed in a Phase 1b Myelofibrosis Trial of AVID200, a Novel TGF-beta 1 & 3 Inhibitor

Jennifer Schram Forbius (Formation Biologics), Portfolio News, Press Release

Investigator-initiated trial to evaluate AVID200’s safety, anti-fibrotic activity, and ability to restore hematopoiesis in patients with myelofibrosis AVID200 is a rationally designed, highly potent inhibitor of TGF-beta 1 & 3, the principal drivers of fibrosis in myelofibrosis and other fibrotic …

Forbius Announces First Patient Dosed in Phase 2a Triple Negative Breast Cancer (TNBC) Trial of AVID100, a Novel, Tumor-Specific Anti-EGFR ADC

Jennifer Schram Forbius (Formation Biologics), Portfolio News, Press Release

This trial evaluates the efficacy of AVID100 in TNBC patients with EGFR-overexpression 20% of TNBC patients highly overexpress EGFR; there is no approved targeted therapy AVID100 is the most advanced, broadly active anti-EGFR ADC in clinical development, targeting both wild-type …

Forbius’ AVID100, a Novel Anti-EGFR ADC, Reports Positive Phase 1 Data at AACR: Exceptionally High RP2D Established, Phase 2 in SCCHN and sqNSCLC Ongoing

Jennifer Schram Forbius (Formation Biologics), Portfolio News, Press Release

AVID100 is the only clinical-stage anti-EGFR ADC that targets both wild-type and mutant forms of EGFR with limited off-tumor toxicity due to novel mechanism of action Phase 1 confirmed that AVID100 was well-tolerated and established a recommended phase 2 dose …

Forbius Collaborates with the Icahn School of Medicine at Mount Sinai & the Myeloproliferative Neoplasm Research Consortium to Evaluate AVID200

Jennifer Schram Forbius (Formation Biologics), Portfolio News, Press Release

MPN-RC sponsored, NIH-supported Phase 1/2 trial in myelofibrosis to commence imminently TGF-beta is a central driver of bone marrow fibrosis in myelofibrosis AVID200 selectively inhibits TGF-beta 1 & 3, the principal fibrotic TGF-beta isoforms, while sparing TGF-beta 2, a positive …

Forbius Announces the First Patient Dosed in a Phase 1 Oncology Trial of AVID200, a Novel TGF-beta 1 & 3 Inhibitor

Jennifer Schram Forbius (Formation Biologics), Portfolio News, Press Release

AVID200 is a rationally designed and highly potent TGF-beta 1 & 3 inhibitor Best-in-class efficacy and safety potential by selectively targeting principal oncogenic TGF-beta isoforms Reverses immunosuppression and renders tumors sensitive to checkpoint blockade in pre-clinical models Jan. 7, 2019 …

Forbius’ AVID200 IND Receives Clearance from the FDA to Start Phase 1 Scleroderma Clinical Trial

Ahmed Khan Forbius (Formation Biologics), Portfolio News

Forbius announced today that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application for AVID200, an isoform-selective TGF-β inhibitor. This enables the company to begin a Phase 1 clinical study to evaluate AVID200 as a potential treatment for diffuse cutaneous systemic …